US President Donald Trump has set his sights on Ireland’s pharmaceutical industry, announcing plans to impose tariffs on pharmaceuticals imported from the country. This move is part of Trump’s broader effort to reshore America’s drug production industry, as he claims the US “doesn’t make anything” in terms of drugs and medicines.
Ireland has become a significant offshore manufacturing hub for US pharmaceutical companies, with around €36bn (£30bn) worth of pharmaceuticals and chemicals exported to the US in 2023. Trump’s tariffs could potentially disrupt this lucrative trade relationship.
The Irish economy is expected to grow by 3% this year and 2.8% next year, but the Economic and Social Research Institute (ESRI) warns that US tariffs could hurt key sectors like pharmaceuticals. Conor O’Toole, an ESRI researcher, notes that changes in US tariffs and policy will have a notable impact on Ireland.
Trump’s tariff policy aims to protect American businesses and boost manufacturing in the US. However, critics argue that tariffs are essentially taxes on trade, which can lead to higher costs for businesses and consumers. As the situation unfolds, it’s clear that Ireland’s pharmaceutical industry will be closely watching the developments.